<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01090323</url>
  </required_header>
  <id_info>
    <org_study_id>CICL670A0109E1</org_study_id>
    <secondary_id>EudraCT no. 2004-000597-31</secondary_id>
    <nct_id>NCT01090323</nct_id>
    <nct_alias>NCT00171197</nct_alias>
  </id_info>
  <brief_title>Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).</brief_title>
  <official_title>A One Year Open Label, Non-comparative Extension to a Randomized, Multicenter, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration (LIC) of Repeated Doses of 5-30mg/kg/Day ICL670 Relative to Deferoxamine (DFO) in Sickle Cell Disease (SCD) Patients With Transfusional Hemosideresis (THS) [Amendment 3: Extension Prolonged to 4-years]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The safety, tolerability, effects on liver iron concentration and pharmacokinetics of ICL670
      is studied in sickle cell disease patients with transfusional hemosiderosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment period started once the patient completed the core study and signed informed
      consent. It is continued for up to 4 years. Safety parameters were assessed every 4 weeks.
      Eye and Ear examinations were performed on a yearly basis. To further investigate the extent
      of iron overload, serum ferritin, iron, and transferrin were monitored every four weeks. The
      Program Safety Board monitored the safety of ICL670 during the study to evaluate and
      categorize any serious case reported in association with ICL670.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events After Start of ICL670</measure>
    <time_frame>0 - 60 months</time_frame>
    <description>Safety as assessed by the number of participants with adverse event or death after the start of ICL670.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Ferritin From Start of ICL670 to End of Study</measure>
    <time_frame>0 - 60 months</time_frame>
    <description>The main efficacy variable was change in serum ferritin in response to therapy with ICL670. Due to variability of serum ferritin, end of study was considered as the mean of at most the last 3 available observations after the start of ICL670.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">185</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>ICL670</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ICL670</intervention_name>
    <description>Daily doses of ICL670 were taken orally 30 minutes before breakfast. The doses range from 5-40 mg/kg and were determined based on the patient's trend in serum ferritin over time during the core study (0109) and on the frequency of blood transfusions the patient received. The treatment duration was up to 4 years.</description>
    <arm_group_label>ICL670</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients were included who met the following criteria:

          -  Completion of the core [Study 0109]

          -  Serum ferritin greater than or equal to 500 µg/L

          -  Ability to comply with all study-related procedures, medications, and evaluations

          -  Sexually active post-menarche female patients must use double-barrier contraception,
             oral contraceptive plus barrier contraceptive, or must have undergone clinically
             documented total hysterectomy and/or oophorectomy, tubal ligation or be postmenopausal
             defined by amenorrhea for at least 12 months.

          -  Written informed consent and assent by the patient and or their parents or legal
             guardian.

        Additional inclusion criteria for pediatric patients The definition of the term 'pediatric'
        for enrollment and study conduct was in accordance with local law. Parents or the legal
        guardians were fully informed by the investigator as to the requirements of the study. The
        pediatric patients themselves were informed according to their capabilities in a language
        and terms that they were able to understand. Written informed consent was obtained from
        their legal guardian on the patient's behalf in accordance with national legislation. If
        capable, all patients had to also personally sign their written informed consent.

        Exclusion Criteria:

        Patients who met the following criteria were to be excluded:

          -  History of non-compliance to medical regimens and patients who are considered
             potentially unreliable and/or not cooperative

          -  Serum creatinine above the age-appropriate upper limit of normal within one week prior
             to entry

          -  Patients with ALT ≥ 500 U/L within one week prior to entry

          -  Evidence of chelation-related cataracts or hearing loss within 4 weeks prior to
             baseline

          -  Pregnancy (as indicated by serum β-HCG pregnancy test for all female patients with the
             potential to become pregnant) and patients who are breastfeeding

          -  Patients treated with systemic investigational drug within 4 weeks prior to or with
             topical investigational drug within 7 days prior to the baseline visit

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama College of Medicine</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital &amp; Research Center at Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>90609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Science Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Joseph Children's Hospital of Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grady Hospital, Georgia Comprehensive Sickle Cell Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Georgia</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSUHSC Dept of Pediatrics</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Methodist Hospital</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yasin</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Health Richland</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santee Hematology/Oncology</name>
      <address>
        <city>Sumter</city>
        <state>South Carolina</state>
        <zip>29150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude's Children Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Memorial Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of the King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2010</study_first_submitted>
  <study_first_submitted_qc>March 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2010</study_first_posted>
  <results_first_submitted>December 21, 2010</results_first_submitted>
  <results_first_submitted_qc>December 21, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 20, 2011</results_first_posted>
  <last_update_submitted>May 3, 2011</last_update_submitted>
  <last_update_submitted_qc>May 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Deferasirox</keyword>
  <keyword>ICL670A</keyword>
  <keyword>Iron chelators</keyword>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Transfusional Hemosiderosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferoxamine</mesh_term>
    <mesh_term>Deferasirox</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ICL670</title>
          <description>Participants treated with ICL670 during the Core Study 0109(NCT00067080) and during the extension phase. ICL670 was administered orally once a day based on the participant's body weight.</description>
        </group>
        <group group_id="P2">
          <title>Crossover</title>
          <description>Participants treated with Deferoxamine (DFO) during the Core Study 0109 (NCT00067080) and treated with ICL670 during the extension phase. ICL670 was administered orally once a day based on the participant's body weight.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Lab Values</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Test Procedure Results</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Condition no longer requires drug</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Stopped end of core</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Stopped end of extension 1#</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ICL670</title>
          <description>Participants treated with ICL670 during the Core Study 0109(NCT00067080) and during the extension phase. ICL670 was administered orally once a day based on the participant's body weight.</description>
        </group>
        <group group_id="B2">
          <title>Crossover</title>
          <description>Participants treated with Deferoxamine (DFO) during the Core Study 0109 (NCT00067080) and treated with ICL670 during the extension phase. ICL670 was administered orally once a day based on the participant's body weight.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="132"/>
            <count group_id="B2" value="53"/>
            <count group_id="B3" value="185"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;12 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 - &lt;16 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 - &lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events After Start of ICL670</title>
        <description>Safety as assessed by the number of participants with adverse event or death after the start of ICL670.</description>
        <time_frame>0 - 60 months</time_frame>
        <population>The primary analysis was on Safety Analysis Set which comprised all participants who received at least one dose of ICL670 during the core/extension phase of the study. All participants previously treated with ICL670/DFO for 52weeks in the core study.</population>
        <group_list>
          <group group_id="O1">
            <title>ICL670</title>
            <description>Participants treated with ICL670 during the Core Study 0109(NCT00067080) and during the extension phase. ICL670 was administered orally once a day based on the participant's body weight.</description>
          </group>
          <group group_id="O2">
            <title>Crossover</title>
            <description>Participants treated with Deferoxamine (DFO) during the Core Study 0109 (NCT00067080) and treated with ICL670 during the extension phase. ICL670 was administered orally once a day based on the participant's body weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events After Start of ICL670</title>
          <description>Safety as assessed by the number of participants with adverse event or death after the start of ICL670.</description>
          <population>The primary analysis was on Safety Analysis Set which comprised all participants who received at least one dose of ICL670 during the core/extension phase of the study. All participants previously treated with ICL670/DFO for 52weeks in the core study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131" spread="10.66"/>
                    <measurement group_id="O2" value="49" spread="11.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Ferritin From Start of ICL670 to End of Study</title>
        <description>The main efficacy variable was change in serum ferritin in response to therapy with ICL670. Due to variability of serum ferritin, end of study was considered as the mean of at most the last 3 available observations after the start of ICL670.</description>
        <time_frame>0 - 60 months</time_frame>
        <population>The primary analysis was on Full Analysis Set which comprised all participants who received at least one dose of ICL670 during the core or the extension phase of the study. All participants previously treated with ICL670 or DFO for 52 weeks in the core study were eligible for enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>ICL670</title>
            <description>Participants treated with ICL670 during the Core Study 0109(NCT00067080) and during the extension phase. ICL670 was administered orally once a day based on the participant's body weight.</description>
          </group>
          <group group_id="O2">
            <title>Crossover</title>
            <description>Participants treated with Deferoxamine (DFO) during the Core Study 0109 (NCT00067080) and treated with ICL670 during the extension phase. ICL670 was administered orally once a day based on the participant's body weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Ferritin From Start of ICL670 to End of Study</title>
          <description>The main efficacy variable was change in serum ferritin in response to therapy with ICL670. Due to variability of serum ferritin, end of study was considered as the mean of at most the last 3 available observations after the start of ICL670.</description>
          <population>The primary analysis was on Full Analysis Set which comprised all participants who received at least one dose of ICL670 during the core or the extension phase of the study. All participants previously treated with ICL670 or DFO for 52 weeks in the core study were eligible for enrollment.</population>
          <units>µg/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-245.5" lower_limit="-8701.3" upper_limit="7626.5"/>
                    <measurement group_id="O2" value="-134.3" lower_limit="-6124.0" upper_limit="5136.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ICL670</title>
          <description>Participants treated with ICL670 during the Core Study 0109(NCT00067080) and during the extension phase. ICL670 was administered orally once a day based on the participant's body weight.</description>
        </group>
        <group group_id="E2">
          <title>Crossover</title>
          <description>Participants treated with Deferoxamine (DFO) during the Core Study 0109 (NCT00067080) and treated with ICL670 during the extension phase. ICL670 was administered orally once a day based on the participant's body weight.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute chest syndrome</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Anaemia haemolytic autoimmune</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Haemolysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hypersplenism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Spleen disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Sickle cell anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Sickle cell anaemia with crisis</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Catheter related complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Catheter thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Granuloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hepatic sequestration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Catheter bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Central line infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Mononucleosis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Citrate toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Collapse of lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Haemolytic transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Biopsy liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Blood amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Blood iron increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pregnancy test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Total lung capacity decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Iron overload</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Osteolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Complex partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Intraventricular haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Enuresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Priapism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pulmonary thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Catheter placement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Catheter removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Central venous catheterisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Jugular vein distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Sickle cell anaemia with crisis</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular icterus</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Allergic transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Serum ferritin increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

